Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
FDA Approved Coherus’ CIMERLI as the First and Only Interchangeable Biosimilar to Lucentis for All Five Indications, with 12 Months of Interchangeability Exclusivity
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
Mizuho Maintains Buy on Coherus BioSciences, Lowers Price Target to $25
Mizuho analyst Salim Syed maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $30 to $25.
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways:
Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule
The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter
